Rare Disease Contract Research Organization (CRO) Market Report 2026

Rare Disease Contract Research Organization (CRO) Market Overview

• Rare Disease Contract Research Organization (CRO) market size has reached to $2.07 billion in 2025 • Expected to grow to $3.16 billion in 2030 at a compound annual growth rate (CAGR) of 8.9% • Growth Driver: Growth In Gene And Cell Therapy Pipelines Driving The Market Due To Rising Demand For Curative Treatments For Rare And Genetic Diseases • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rare Disease Contract Research Organization (CRO) Market?

A rare disease contract research organization (CRO) is a specialized service provider that assists pharmaceutical and biotechnology companies in designing and executing clinical research and trials for rare or orphan diseases. It delivers targeted expertise to address challenges such as limited patient populations and the complex nature of these conditions. The main service types of rare disease contract research organization (CRO) include drug development strategy, clinical trial management, patient recruitment and retention services, data management and biostatistics, regulatory affairs and consulting, pharmacovigilance services, medical writing and documentation, decentralized clinical trial services, and other service types. Drug development strategy refers to specialized consulting and planning services that support the design and execution of clinical development programs for rare diseases with high precision and regulatory alignment. They are used across phases including pre clinical, phase one, phase two, phase three, and phase four and are focused on therapeutic areas such as oncology, neurology, cardiovascular disorders, metabolic disorders, genetic disorders, hematology, immunology, rare infectious diseases, and other rare indications. The various delivery models involved are on site clinical trials, decentralized clinical trials, and hybrid clinical trials, and they are used by several end users such as pharmaceutical and biotechnology companies, non profit and government organizations, academic and research institutes, and others.

What Is The Rare Disease Contract Research Organization (CRO) Market Growth Forecast?

The rare disease contract research organization (CRO) market size is expected to see strong growth in the next few years. It will grow to $3.16 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to advancement in genomic sequencing enabling early rare disease detection, increasing orphan drug approvals driving CRO outsourcing demand, expansion of precision medicine accelerating niche clinical research, rising adoption of decentralized trials improving global patient access, growing biotech investment in rare disease therapeutics. Major trends in the forecast period include adaptive patient-centric trial designs for ultra-rare disease cohorts, expansion of global rare disease patient registry ecosystems, increased adoption of decentralized and hybrid rare disease clinical trials, growth of specialized orphan drug regulatory consulting services, rising integration of real-world evidence in rare disease clinical validation.

Global Rare Disease Contract Research Organization (CRO) Market Segmentation

1) By Service Type: Drug Development Strategy, Clinical Trial Management, Patient Recruitment And Retention Services, Data Management And Biostatistics, Regulatory Affairs And Consulting, Pharmacovigilance Services, Medical Writing And Documentation, Decentralized Clinical Trial Services, Other Service Types 2) By Phase: Pre Clinical, Phase One, Phase Two, Phase Three, Phase Four 3) By Therapeutic Area: Oncology, Neurology, Cardiovascular Disorders, Metabolic Disorders, Genetic Disorders, Hematology, Immunology, Rare Infectious Diseases, Other Rare Indications 4) By Delivery Model: On Site Clinical Trials, Decentralized Clinical Trials, Hybrid Clinical Trials 5) By End User: Pharmaceutical And Biotechnology Companies, Non Profit And Government Organizations, Academic And Research Institutes, Other End Users Subsegments: 1) By Drug Development Strategy: Preclinical Development Planning, Clinical Development Planning, Target Identification And Validation, Portfolio Strategy Optimization 2) By Clinical Trial Management: Phase One Trial Management, Phase Two Trial Management, Phase Three Trial Management, Site Monitoring And Coordination 3) By Patient Recruitment And Retention Services: Patient Identification Services, Patient Enrollment Support, Patient Engagement Programs, Patient Retention Strategies 4) By Data Management And Biostatistics: Clinical Data Collection And Processing, Statistical Analysis And Modeling, Database Design And Management, Data Quality Assurance 5) By Regulatory Affairs And Consulting: Regulatory Strategy Development, Submission Preparation And Filing, Compliance And Audit Support, Regulatory Advisory Services 6) By Pharmacovigilance Services: Adverse Event Monitoring, Safety Data Analysis, Risk Management Planning, Signal Detection And Reporting 7) By Medical Writing And Documentation: Clinical Study Report Writing, Protocol Development Documentation, Regulatory Writing Services, Scientific Publication Writing 8) By Decentralized Clinical Trial Services: Remote Patient Monitoring, Virtual Trial Management, Home Healthcare Services, Digital Data Collection Solutions 9) By Other Service Types: Rare Disease Consulting Services, Genetic Research Support, Biomarker Development Services, Translational Research Services

What Are The Drivers Of The Rare Disease Contract Research Organization (CRO) Market?

The growth in gene and cell therapy pipelines is expected to propel the growth of the rare disease contract research organization market going forward. Gene and cell therapy are advanced treatments that modify genes or use engineered cells to correct disease at its root cause. Gene and cell therapy are increasing mainly due to the rising prevalence of chronic and rare genetic diseases, as these therapies offer targeted, potentially curative treatments by addressing the underlying genetic or cellular defects rather than just managing symptoms. Rare disease contract research organizations (CROs) support gene and cell therapy by designing and managing highly specialized clinical trials, enabling efficient patient identification and recruitment for rare genetic conditions, ensuring regulatory compliance, and handling complex data and logistics required for these advanced, precision-based therapies. For instance, in March 2024, according to IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, global spending on cell and gene therapies surged to $5.9 billion in 2023, an increase of 38% from 2022. Therefore, the growth in gene and cell therapy pipelines is driving the growth of the rare disease contract research organization market. The growth in research and development activities is expected to propel the growth of the rare disease contract research organization (CRO) market going forward. Research and development (R&D) activities are work carried out to create new knowledge and apply it to develop or improve products, services, or technologies. Rising research and development activities are driven by the growing need for continuous innovation to remain competitive in rapidly evolving markets, prompting companies to invest in advanced products and technologies that address changing consumer demands and industry trends. Rare disease contract research organizations (CROs) support research and development by providing specialized expertise, infrastructure, and patient recruitment capabilities that help accelerate the design, execution, and management of complex rare disease clinical trials and drug development programs. For instance, in 2023, according to the Office for National Statistics, a UK-based government agency, the UK government’s net spending on research and development (R&D) increased to £17.4 ($22.1 billion) in 2023, up from £16.1 billion ($20.45 billion) in 2022, marking an 8.2% rise. Therefore, the growth in research and development activities is driving the growth of the rare disease contract research organization market.

Key Players In The Global Rare Disease Contract Research Organization (CRO) Market

Major companies operating in the rare disease contract research organization (cro) market are Thermo Fisher Scientific Inc., IQVIA Holdings Inc., Laboratory Corporation of America Holdings, ICON plc, SGS SA, Charles River Laboratories International Inc., Fortrea Holdings Inc., Medpace Holdings Inc., ALS Limited, PSI CRO AG, Ratos AB, Precision for Medicine Inc., Allucent, QPS Holdings LLC, Alira Health SAS, Rho Inc., Veristat LLC, Quanticate Ltd., Cromos Pharma LLC, Frontage Laboratories Inc., ProTrials Research Inc., PROMETRIKA LLC, Machaon Diagnostics Inc., Sofpromed GmbH

What Are Latest Mergers And Acquisitions In The Rare Disease Contract Research Organization (CRO) Market?

In May 2023, Worldwide Clinical Trials, a US-based, full-service contract research organization for rare diseases, partnered with Every Cure to speed up the discovery and development of therapies for rare disease patients through drug repurposing and clinical research support. The partnership aims to improve the development of treatments for rare diseases by using strategies to repurpose drugs, analyzing data with AI, and making clinical trials more efficient. Every Cure is a US-based nonprofit organization focused on identifying new uses for existing drugs.

Regional Outlook/Insights

North America was the largest region in the rare disease contract research organization (CRO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Rare Disease Contract Research Organization (CRO) Market?

The rare disease contract research organization (CRO) market includes revenues earned by entities by providing services such as natural history studies, real-world evidence generation, biomarker research, and translational research support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rare Disease Contract Research Organization (CRO) Market Report 2026?

The rare disease contract research organization (cro) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rare disease contract research organization (cro) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.